ODTX Odyssey Therapeutics, Inc. - Common Stock
$23.65
Price · Aug 19, 2026
Fundamentals as of Aug 6, 2026
52W Range
$15–$24
96% of range
Analyst Rating
BUY
11 analysts
Price Target
$33
+40% upside
P/E (TTM)
—
ROE
—
Net Profit Margin
—
ODTX Stock Snapshot Price, market cap, P/E, EPS, ROE, debt/equity, 52-week range
Price
$23.65
Market Cap
—
P/E (TTM)
—
EPS (TTM)
—
Revenue (TTM)
—
Div Yield
—
ROE
—
Debt/Equity
—
52W Range
$15 – $24
ODTX Stock Price Chart Daily OHLCV with technical indicators — pan, zoom, and customize your view
Configure
10-Year Performance Revenue, net income, margins and EPS trends
Revenue & Net Income
—
EPS
—
Free Cash Flow
—
Margins
—
Valuation P/E, P/S, P/B, EV/EBITDA ratios — is the stock expensive or cheap?
Metric
5Y trend
ODTX
Peer Median
Profitability Gross, operating and net margins; ROE, ROA, ROIC
Metric
5Y trend
ODTX
Peer Median
Financial Health Debt, liquidity, solvency — balance sheet strength
Metric
5Y trend
ODTX
Peer Median
Growth Revenue, EPS and net income growth: YoY, 3Y CAGR, 5Y CAGR
Metric
5Y trend
ODTX
Peer Median
Capital Efficiency Asset turnover, inventory turnover, receivables turnover
Metric
5Y trend
ODTX
Peer Median
ODTX Analyst Consensus Bullish and bearish analyst opinions, 12-month price target, upside
BUY
11 analysts
- Strong Buy 4 36.4%
- Buy 6 54.5%
- Hold 1 9.1%
- Sell 0 0.0%
- Strong Sell 0 0.0%
12-Month Price Target
3 analysts · 2026-08-13
Median
$30.00
Mean
$33.00
← Below all targets
$23.65
Low
$29.00
High
$40.00
Median target
$30.00
+26.8%
Mean target
$33.00
+39.5%
Earnings History EPS actual vs estimate, surprise %, beat rate, next earnings date
Avg Surprise
-3.1%
| Period | EPS Actual | EPS Est | Surprise |
|---|---|---|---|
| June 30, 2026 | $-1.74 | $-1.03 | -0.71% |
| March 31, 2026 | $-6.77 | $-1.28 | -5.5% |
Peer comparison (GICS sub-industry) Key metrics vs sector peers
| Ticker | Market Cap | P/E | Rev YoY | Net Margin | ROE | Gross Margin |
|---|---|---|---|---|---|---|
| ODTX | — | — | — | — | — | — |
| SANA | $1.09B | -4.2 | — | — | -172.3% | — |
| VOR | $506M | -0.2 | — | — | 83.4% | — |
| SVRA | $1.23B | -11.4 | — | — | -73.4% | — |
| KURA | $913M | -3.3 | 25.2% | -413.0% | -116.2% | — |
| AVTX | $336M | -3.1 | -86.6% | -132642.4% | -83.4% | — |
| JANX | $833M | -7.5 | -5.5% | -1136.2% | -11.7% | — |
| ANNX | $750M | -3.7 | — | — | -100.7% | — |
Full Fundamentals All metrics by year — income statement, balance sheet, cash flow
Balance Sheet 24
| Metric | Trend | 2025 |
|---|---|---|
| Cash & Equivalents | $42M | |
| Short-term Investments | $140M | |
| Receivables | $0 | |
| Prepaid Expense | $9M | |
| Current Assets | $191M | |
| PP&E (Net) | $7M | |
| PP&E (Gross) | $21M | |
| Accum. Depreciation | $14M | |
| Goodwill | $14M | |
| Intangibles | $262.0K | |
| Other Non-current Assets | $3M | |
| Total Assets | $270M | |
| Accounts Payable | $8M | |
| Accrued Liabilities | $13M | |
| Current Liabilities | $26M | |
| Capital Leases | $22M | |
| Total Liabilities | $55M | |
| Common Stock | $0 | |
| Paid-in Capital | $80M | |
| Retained Earnings | $-568M | |
| AOCI | $245.0K | |
| Stockholders' Equity | $-488M | |
| Liabilities + Equity | $270M | |
| Shares Outstanding | 2,306,207 |
Income Statement 14
| Metric | Trend | Q2 2026 | Q1 2026 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $959.0K | $2M | |
| R&D Expense | $36M | $32M | $30M | $39M | |
| SG&A Expense | $11M | $7M | $13M | $8M | |
| Operating Expenses | $55M | $40M | $43M | $41M | |
| Operating Income | $-55M | $-40M | $-42M | $-39M | |
| Other Non-op | $-138.0K | $-117.0K | $-154.0K | $-289.0K | |
| Pretax Income | $-53M | $-38M | $-41M | $-38M | |
| Income Tax | $-8.0K | $63.0K | $30.0K | $140.0K | |
| Net Income | $-53M | $-38M | $-41M | $-38M | |
| EPS (Basic) | $-1.74 | $-6.77 | $-29.54 | $-39.37 | |
| EPS (Diluted) | $-1.74 | $-6.77 | $-29.54 | $-39.37 | |
| Shares (Basic) | 30,277,051 | 5,655,716 | 1,395,695 | 976,146 | |
| Shares (Diluted) | 30,277,051 | 5,655,716 | 1,395,695 | 976,146 | |
| EBITDA | $-55M | $-39M | · | · |
Balance Sheet 24
| Metric | Trend | Q2 2026 | Q1 2026 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | $82M | $36M | · | · | |
| Short-term Investments | $229M | $140M | · | · | |
| Receivables | $0 | $0 | · | · | |
| Prepaid Expense | $11M | $9M | · | · | |
| Current Assets | $321M | $185M | · | · | |
| PP&E (Net) | $5M | $7M | · | · | |
| PP&E (Gross) | $18M | $22M | · | · | |
| Accum. Depreciation | $13M | $15M | · | · | |
| Goodwill | $14M | $14M | · | · | |
| Intangibles | $86.0K | $160.0K | · | · | |
| Other Non-current Assets | $4M | $5M | · | · | |
| Total Assets | $484M | $229M | · | · | |
| Accounts Payable | $8M | $8M | · | · | |
| Accrued Liabilities | $15M | $9M | · | · | |
| Current Liabilities | $28M | $22M | · | · | |
| Capital Leases | $19M | $21M | · | · | |
| Total Liabilities | $63M | $49M | · | · | |
| Common Stock | $5.0K | $0 | · | · | |
| Paid-in Capital | $1.08B | $83M | · | · | |
| Retained Earnings | $-659M | $-606M | · | · | |
| AOCI | $-505.0K | $-147.0K | · | · | |
| Stockholders' Equity | $421M | $-524M | · | · | |
| Liabilities + Equity | $484M | $229M | · | · | |
| Shares Outstanding | 47,891,251 | 2,481,339 | · | · |
Cash Flow 9
| Metric | Trend | Q2 2026 | Q1 2026 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| D&A | $1M | $1M | $1M | $1M | |
| Stock-based Comp | $6M | $3M | $4M | $3M | |
| Other Non-cash | · | $-7M | · | · | |
| Operating Cash Flow | $-35M | $-41M | $-34M | $-39M | |
| CapEx | $186.0K | $148.0K | $29.0K | $927.0K | |
| Investing Cash Flow | $-211M | $35M | $23M | $34M | |
| Financing Cash Flow | $292M | $484.0K | $119M | $200.0K | |
| Net Change in Cash | $46M | $-6M | $108M | $-4M | |
| Free Cash Flow | · | $-41M | · | · |
Profitability 3
| Metric | Trend | Q2 2026 | Q1 2026 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| ROA | -21.8% | -33.4% | · | · | |
| ROE | -25.1% | 14.6% | · | · | |
| ROIC | -13.2% | 7.6% | · | · |
Liquidity & Solvency 2
| Metric | Trend | Q2 2026 | Q1 2026 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Current Ratio | 11.4 | 8.3 | · | · | |
| Quick Ratio | 11.0 | 7.9 | · | · |
Efficiency 1
| Metric | Trend | Q2 2026 | Q1 2026 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Asset Turnover | 0.0 | 0.0 | · | · |
Valuation (TTM) 3
| Metric | Trend | Q2 2026 | Q1 2026 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Market Cap | $896M | · | · | · | |
| P/B | 2.1 | · | · | · | |
| P / Tangible Book | 2.2 | · | · | · |
Financial Statements Income statement, balance sheet, cash flow — annual, last 5 years
My Metrics Your personal watchlist — selected rows from Full Fundamentals
📊
Pick the metrics that matter to you — click the ➕ next to any row in Full Fundamentals above.
Your selection is saved and follows you across all tickers.
Company insiders 13 insiders · 5 officers · 9 directors
| Insider | Role | Last activity | Shares owned | Buys 12m | Sells 12m | Net 12m |
|---|---|---|---|---|---|---|
| Gary D Glick | President and Chief Executive Officer | May 7, 2026 A | 415,973 | 0 | 0 | $0 |
| Jason Haas | Chief Financial Officer | May 8, 2026 P | 62,908 | 1 | 0 | $20,000 |
| Anthony W. Opipari | Interim Chief Medical Officer and Executive Vice President, Translational Medicine | May 11, 2026 M | 7,502 | 0 | 0 | $0 |
| Natalie Dales | Chief of Research Operations and Portfolio Strategy | May 7, 2026 A | — | 0 | 0 | $0 |
| Collin M Todd | Senior Vice President, Strategy and Business Development | May 7, 2026 A | — | 0 | 0 | $0 |
| Nan Li | Director | May 11, 2026 C | 3,333,516 | 1 | 0 | $19,999,998 |
| Shelley Chu | Director | May 11, 2026 P | 11,111 | 1 | 0 | $199,998 |
| Jeffrey M Leiden | Director | May 11, 2026 M | 31,644 | 1 | 0 | $100,000 |
| Dimension Capital II, L.P. | Director | May 8, 2026 C | 3,333,516 | 1 | 0 | $19,999,998 |
| Valerie Odegard | Director | May 7, 2026 A | — | 0 | 0 | $0 |
| Ourania Tatsis | Director | May 7, 2026 A | — | 0 | 0 | $0 |
| Timothy P Walbert | Director | May 7, 2026 A | — | 0 | 0 | $0 |
| Ian F Smith | Director | May 7, 2026 A | — | 0 | 0 | $0 |
Insiders from SEC Form 3/4/5 filings; net = open-market P/S only
Activists & 5%+ owners 4 positions
Investors who filed SEC Schedule 13D — beneficial ownership above 5% with an intent to influence the issuer (activist stakes, board campaigns, M&A). Each row shows the most recent known state of that filer's position.
| Filer | Filed | Stake | Status | Purpose | Filing |
|---|---|---|---|---|---|
| SR One Capital Management, LLC, SR One Capital Fund I Aggregator, LP, SR One Capital Partners I, LP, SR One Co-Invest IV, LLC, SR One Co-Invest IV-A, LLC, SR One Co-Invest IV Manager, LLC, AMZL, LP, SR One Capital SMA Partners, LP, Simeon George | May 18, 2026 | 8.00% | Initial filing | Passive investment | SEC |
| TPG GP A, LLC, James G. Coulter, Jon Winkelried | May 18, 2026 | 7.80% | Initial filing | — | SEC |
| Jeito II S.L.P., Jeito Capital SAS, Rafaele Tordjman, Sabine Dandiguian | May 15, 2026 | 7.80% | Initial filing | Passive investment | SEC |
| Dimension Management, L.P., Dimension Capital II, L.P., Dimension Capital II GP, LLC, Dimension Management GP, LLC, Adam Goulburn, Zavain Dar, Nan Li | May 15, 2026 | 7.10% | Initial filing | Passive investment | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
ETF ownership Held by 6 ETFs
Weight reflects direct equity holdings (N-PORT) only; leveraged or derivative-based funds may hold additional swap exposure not shown.
| Fund | Weight | Units | As of | Source |
|---|---|---|---|---|
| VXF · VANGUARD INDEX FUNDS | — | — | July 15, 2026 | Daily |
| VTI · VANGUARD INDEX FUNDS | — | — | July 15, 2026 | Daily |
| VTWO · VANGUARD SCOTTSDALE FUNDS | — | — | July 15, 2026 | Daily |
| VTWV · VANGUARD SCOTTSDALE FUNDS | — | — | July 15, 2026 | Daily |
| VTWG · VANGUARD SCOTTSDALE FUNDS | — | — | July 15, 2026 | Daily |
| VTHR · VANGUARD SCOTTSDALE FUNDS | — | — | July 15, 2026 | Daily |